ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Nov 02, 2022 18:34 JST
Source: Eisai
Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
TOKYO, Nov 02, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study" specified post-marketing observational study condition required at the time of approval of antiepileptic agent Inovelon Tablets 100 mg and 200 mg (rufinamide) as an adjunctive therapy to other antiepileptic drugs (AEDs) for treatment of Lennox-Gastaut syndrome (LGS) has been cleared.
In March 2013, the MHLW approved Inovelon as an adjunctive therapy with other antiepileptic drugs for tonic and atonic seizures associated with LGS showing insufficient response to other antiepileptics, with the following condition: "Because of the very limited number of subjects included in the Japanese clinical trials, the applicant is required to conduct a post-marketing observational study in all patients until data from a certain number of patients is accumulated after its launch in the market, in order to identify the background information of patients treated with the product and collect safety and efficacy data on the product in the early post-marketing period, and thereby take necessary measures to ensure proper use of the product."
Based on the safety data in 702 patients and efficacy data in 495 patients submitted to the MHLW as the results of analyses of this all-case study, the MHLW has concluded that the all-case study was conducted properly and the necessary measures to ensure proper use of the product were sufficient to lift the condition.
Eisai will continually strive to promote the proper use of Inovelon and provide information about the product, thereby making further contributions to increase the benefits to patients and their families.
For more information, visit www.eisai.com/news/2022/news202275.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
DENSO Announces Third Quarter Financial Results
Feb 03, 2023 19:24 JST
TOYOTA GAZOO Racing in search of more Swedish snow success
Feb 03, 2023 18:10 JST
Mitsubishi Shipbuilding and INPEX Complete Conceptual Study for Ammonia Bunkering Vessel
Feb 02, 2023 17:03 JST
Fujitsu named to FORTUNE Magazine's 2023 list of "World's Most Admired Companies" for fifth year running
Feb 02, 2023 16:33 JST
Hitachi to Strengthen Business Structure to Accelerate Growth through Digital, Green, and Innovation
Feb 02, 2023 14:19 JST
Fujitsu delivers digital transformation with AI demand forecast service for TORIDOLL noodle shops throughout Japan
Feb 02, 2023 11:36 JST
Compact CO2 Capture System Receives "Awards for Excellence" at the 2022 Nikkei Excellent Products and Services Awards
Feb 01, 2023 16:52 JST
Fujitsu outlines vision for secure and sustainable network technologies at MWC Barcelona 2023
FP
Feb 01, 2023 10:53 JST
Premiere of New Mazda CX-90 Crossover SUV
Feb 01, 2023 09:00 JST
Honda: Production, Sales and Export Results for December, 2022
Jan 31, 2023 11:57 JST
Mazda Production and Sales Results for December 2022 and for January through December 2022
Jan 31, 2023 11:08 JST
DOCOMO Conducts World's First Trial of Transmissive Metasurface on Window to Deliver Indoor Radio Waves to Outdoor Foot of Building
Jan 30, 2023 17:00 JST
Small, Efficient 5G Multisector Antenna Indoor Base Station Achieves World's First Demonstration using 28GHz
Jan 30, 2023 16:35 JST
DOCOMO and YKK AP to Test Signal-permeable Windows Made with Aerogel for Easy Penetration by Radio Waves
Jan 30, 2023 16:13 JST
NEC announces plans for transition to a Company with a Nominating Committee, etc. and implementation of organizational reforms
Jan 30, 2023 15:44 JST
NEC announces executive personnel changes
Jan 30, 2023 15:28 JST
Toyota: Sales, Production, and Export Results for 2022 (January - December)
Jan 30, 2023 13:36 JST
Lecanemab Receives Priority Review Status in Japan
Jan 30, 2023 12:50 JST
Two Hitachi Group Companies to Merge to Expand Robotic SI Business in Japan and ASEAN Countries
Jan 30, 2023 11:08 JST
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project
Jan 27, 2023 15:25 JST
More Latest Release >>
Related Release
Lecanemab Receives Priority Review Status in Japan
1/30/2023 12:50:00 PM JST
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
1/27/2023 11:46:00 AM JST
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
1/19/2023 10:35:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
1/19/2023 9:07:00 AM JST
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
1/18/2023 1:28:00 PM JST
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
1/16/2023 6:56:00 PM JST
Eisai Launches Renewed Sustainability Page
1/13/2023 3:06:00 PM JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
1/11/2023 12:52:00 PM JST
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
1/9/2023 9:55:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
1/9/2023 8:40:00 PM JST
More Press release >>